Results 71 to 80 of about 56,599 (248)

Anticuerpos anti-etanercept en pacientes colombianos con artritis reumatoide [PDF]

, 2017
Con el Objetivo de determinar la presencia de anticuerpos dirigidos contra etanercept en un grupo de pacientes adultos colombianos con diagnóstico de artritis reumatoide tratados con Enbrel® y Etanar® se incluyeron 32 pacientes en el estudio, de los ...
Reyes Beltrán, Benjamín
core  

GP2015: An Etanercept Biosimilar

, 2018
Compliance with Ethical Standards Disclosure: The preparation of this review was not supported by any external funding. Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of ...
Emma D. Deeks (4985339)
core   +1 more source

Five-Year Experience of Etanercept as Adjunct to Intravenous Immunoglobulin for Kawasaki Disease with Coronary Artery Involvement

Journal of Pediatrics: Clinical Practice
Objective: The Etanercept as Adjunctive Treatment for Acute Kawasaki Disease trial was a phase 3, placebo-controlled, randomized trial that evaluated etanercept use for acute Kawasaki disease (KD).
Ryan Rogers, MD, Eyal Sagiv, MD, PhD, Aaron K. Olson, MD, Michael A. Portman, MD   +3 more
doaj   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy

Journal of Infection and Public Health
Background: The risk of infection including tuberculosis (TB) infection or reactivation during biological therapy with the current various clinical application is a major concern. This risk may be higher in countries endemic to TB.
Abdulaziz Boqaeid, Laila Layqah, Amgad Alonazy, Mutaz Althobaiti, Al-zahraa Almahlawi, Abdullah Al-Roqy, Omar Baharoon, Abdullah Alsaeedi, Jinan Shamou, Salim Baharoon   +9 more
doaj   +1 more source

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

Arthritis Care &Research, EarlyView.
Catherine Deffendall, Jodi Backalar, Elizabeth Acevedo Zapata, Adriana Della Porta, Lorin Bibb, Tyler Reese, Charlotte M. Brown   +6 more
wiley   +1 more source

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis Within a Longitudinal Cohort

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis ...
Patricia Remalante‐Rayco, Laura Passalent, Tina Chim, Hannah Vijayan, Manal Alnasser, Zeynep Baskurt, Robert D. Inman, Nigil Haroon, Denis Poddubnyy   +8 more
wiley   +1 more source

Etanercept therapy for psoriasis in a patient with numerous comorbidities

, 2010
A recent study demonstrated an association between psoriasis and dilated cardiomyopathy. Tumour necrosis factor alpha (TNFalpha) may be involved in the pathogenesis of dilated cardiomyopathy and therefore, anti-TNFalpha agents may play a role in the ...
De Simone, Clara, Caldarola, Giacomo, Carbone, Angelo   +2 more
core  

Effect of IT Etanercept on Adjuvant Arthritis

, 2013
Rats were immunized with CFA on day 0 and treated with IT etanercept (100 or 300 μg q.o.d.) beginning on day 1. (A) IT etanercept (Etan) significantly decreased paw swelling (*p = 0.001 for IT saline compared with either IT etanercept group) (
Camille I Svensson (65493), Toni L Jones (65491), Gary S Firestein (504), Deepa Hammaker (65492), Salvatore Albani (65494), Sanna Rosengren (2681), David L Boyle (2680), Linda Sorkin (65495)   +7 more
core   +1 more source

Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Interspecies cross‐reactive protein therapeutics that target conserved epitopes across species are critical for translational research. The present study showcases the engineering of an affibody molecule, originally discovered for binding to human death receptor 5 (hDR5) with 94 nM affinity, to simultaneously acquire cross‐reactivity to murine
Tse‐Han Kuo, Nagamani Vunnam, Jonathan N. Sachs, Benjamin J. Hackel   +3 more
wiley   +1 more source